Prevalence and risk factors of dry eye disease in patients treated with aromatase inhibitors for breast cancer.

Autor: Machairoudia G; 2nd Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Kazantzis D; 2nd Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Chatziralli I; 2nd Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Kampoli K; Hematology Oncology Unit, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Ntavatzikos A; Hematology Oncology Unit, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Theodossiadis P; 2nd Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Koumarianou A; Hematology Oncology Unit, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Jazyk: angličtina
Zdroj: Clinical & experimental optometry [Clin Exp Optom] 2024 May; Vol. 107 (4), pp. 415-419. Date of Electronic Publication: 2023 Sep 12.
DOI: 10.1080/08164622.2023.2239247
Abstrakt: Clinical Relevance: Treatment with aromatase inhibitors (AIs) in patients with breast cancer can lead to dry eye disease (DED).
Background: The purpose of the study is to determine the prevalence and risk factors of DED in patients treated with AIs for breast cancer.
Methods: Participants in this cross-sectional study were patients with breast cancer treated with AIs. Demographic and clinical data, including age, sex, type of cancer, stage, grade, duration of treatment and adjuvant chemotherapy and/or radiotherapy were collected. All patients underwent a detailed ophthalmic examination, as well as Tear Break up Time (TBUT) and Schirmer test, while Ocular Surface Disease Index (OSDI) questionnaires were administered. Based on the clinical findings, a diagnosis of DED was made, and prevalence was calculated. Univariate analysis of the association of different variables with DED was performed. A logistic regression analysis was done to identify risk factors for DED among study population.
Results: A total of 102 participants were included in the study. The mean age of patients was 62.4 ± 10.8 years. A total of 77 out of 102 patients (75.5%) had ductal, 16 (15.7%) lobular and 9 (8.8%) other types of breast cancer. A total of 83 patients (81.4%) received chemotherapy and 70 patients (68.6%) received radiotherapy. The mean duration of treatment was 24.4 ± 18.9 months. The prevalence of DED in the study sample was 69.6%. Patients who received radiotherapy (OR = 3.31, 95%CI = 1.30-7.82, p  = 0.01) or were under treatment with AIs for more than 24 months (OR = 3.53, 95%CI = 1.47-9.21, p  = 0.002) were found to have an increased risk of DED.
Conclusion: There was a high prevalence of DED among the study population. Radiotherapy and duration of treatment with AIs were independently associated with DED.
Databáze: MEDLINE
Externí odkaz: